Literature DB >> 17627066

A long way: history of the prophylactic papillomavirus vaccine.

Martin Müller1, Lutz Gissmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17627066      PMCID： PMC3850800          DOI： 10.1155/2007/939634

Source DB:  PubMed          Journal:  Dis Markers        ISSN： 0278-0240            Impact factor:   3.434


× No keyword cloud information.
  4 in total

1.  Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines.

Authors:  M Tahir Waheed; Nadja Thönes; Martin Müller; S Waqas Hassan; N Mona Razavi; Elke Lössl; Hans-Peter Kaul; Andreas G Lössl
Journal:  Transgenic Res       Date:  2010-06-19       Impact factor: 2.788

2.  Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Authors:  Tilo Senger; Lysann Schädlich; Sonja Textor; Corinna Klein; Kristina M Michael; Christopher B Buck; Lutz Gissmann
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

3.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

Review 4.  [Public awareness of human papilloma virus infection in the head and neck area: an appeal for precision in diagnostics and for public health awareness].

Authors:  M Hoffmann; A S Hoffmann; S Tribius
Journal:  HNO       Date:  2012-11       Impact factor: 1.284
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.